The impact on hospital resource utilisation of treatment of hepatic encephalopathy with rifaximin‐α

Abstract

Initiation of treatment with rifaximin-α was associated with a marked reduction in the number of hospital admissions and hospital length of stay. These data suggest that treatment of patients with rifaximin-α for hepatic encephalopathy was generally cost saving.